Novo Holdings establishes new firm managed by biotech veterans

Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.
Photo: Novo Holdings / PR
Photo: Novo Holdings / PR
by christopher due karlsson, translated by daniel pedersen

Novo Holdings, the holdings company which owns Novo Nordisk, has founded a Danish private limited company named Aloop Therapeutics, with Orphazyme co-founder Thomas Kirkegaard Jensen as a director and Sandion Oncology CEO Bo Rode Hansen as chair of the board, according to a filing on the Danish Central Business Register (CVR).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading